NICE has recommended interim NHS funding for Bristol-Myers Squibb’s cancer immunotherapy, Opdivo to prevent early stage skin cancer from recurring, overturning a decision earlier this year
A second cut-price biosimilar of Amgen’s Neulasta (pegfilgrastim) long-acting white blood cell booster is to hit the EU market after the European Commission approved Mundipharma’s Pelmeg.
